India Pharma Outlook Team | Thursday, 27 August 2026
The pharma industry is entering a busy phase for drug launches as new therapies are gaining clearance across major markets.
Recent regulatory decisions show companies expanding access to innovative medicines while pursuing new markets and indications.
Revolution Medicines has won USFDA approval for its targeted pancreatic cancer drug. Meanwhile, Novo Nordisk has moved closer to launching oral Wegovy in China.
GSK has also expanded the use of Tivicay PD to newborns with HIV. Alongside these developments, Cipla faces fresh FDA scrutiny at its Pithampur facility.
Together, the recent developments show how drugmakers are balancing innovation and market expansion with the need to meet stringent regulatory standards.
Revolution Medicines has received expedited FDA approval for Rasonque (daraxonrasib), a once-daily oral treatment for adults with metastatic pancreatic adenocarcinoma. The approval covers patients who have received at least one prior systemic therapy or who cannot receive multi-agent systemic therapy. The drug targets multiple forms of RAS, a protein that drives tumor growth in pancreatic cancer.
The approval marks an important development in targeted oncology. In a Phase 3 trial involving 500 patients, Rasonque delivered a median overall survival of 13.2 months. Patients receiving standard chemotherapy recorded 6.7 months. The drug reduced the risk of death by 60 per cent compared with chemotherapy.
Rasonque is now available in the US. Revolution Medicines has set the wholesale acquisition cost at USD 39,800 for a 30-day supply. The company has also launched a patient support program to help eligible patients with insurance, financial assistance and treatment education.
Also Read: How Regulatory Readiness Can Shape Pharma's Global Growth
Novo Nordisk has taken another step towards expanding its obesity portfolio in China. The country’s drug regulator has accepted the company’s marketing application for the oral version of Wegovy. The decision does not represent final approval, but it moves the medicine closer to a potential launch in the Chinese market.
The oral formulation could give patients an alternative to injectable Wegovy. This could become increasingly important as pharmaceutical companies compete for a larger share of the global obesity-treatment market.
China has also become an increasingly important battleground for GLP-1 medicines. Novo Nordisk is competing with Eli Lilly and other companies seeking to expand their presence in the country's rapidly developing obesity market.
The latest regulatory developments also include several important label expansions and international approvals. The FDA has approved GSK's Tivicay PD for newborns with HIV who weigh at least 2 kg. The medicine can be used with other antivirals in treatment-naive and treatment-experienced patients, with specific exclusions. The approval expands access to treatment for a patient group that has historically had fewer options.
GSK has also secured its first global approval for Hibsago, its chronic hepatitis B treatment, in Japan. Takeda's Orzeyful, an oral orexin receptor 2 agonist for narcolepsy type 1, also received approval in Japan. Meanwhile, Johnson & Johnson and other drugmakers have secured additional regulatory expansions across oncology and other therapeutic areas.
Eli Lilly has also entered another important market with Foundayo. The UK's MHRA approved the oral GLP-1 drugs for weight management and Type 2 diabetes. The UK became the first European market to approve the medicine.
These developments point to a wider industry strategy. Drugmakers are increasingly using regulatory approvals to extend established products into new markets, patient groups and treatment settings.
The approval momentum comes alongside continuing regulatory pressure on manufacturing operations. Cipla's Pithampur formulations facility in Madhya Pradesh received seven observations from the USFDA following a follow-up cGMP inspection conducted from August 17 to August 25.
The observations were issued through Form 483. Cipla said it will work closely with the FDA and address the findings within the stipulated timeframe. The company has not disclosed the nature of the observations.
Pithampur remains an important manufacturing site for Cipla and supplies regulated markets, including the US. The facility previously received a Warning Letter in 2023 after an inspection resulted in eight observations. That regulatory action delayed Cipla's plans for a generic version of GSK's Advair Diskus. The company received final marketing approval for the generic in July this year.
The latest approvals show that pharma growth is increasingly linked to targeted therapies, new formulations and geographic expansion. Rasonque demonstrates the potential of precision approaches in difficult-to-treat cancers. Oral Wegovy and Foundayo highlight how drugmakers are moving the GLP-1 market beyond injectable treatments.
However, commercial expansion still depends on regulatory execution. Cipla's latest FDA observations reinforce the importance of manufacturing compliance even when companies are pursuing major product launches. The broader picture suggests that the next phase of pharma competition will depend not only on developing innovative medicines, but also on how quickly companies can secure approvals, maintain quality standards and bring those medicines to patients across markets.
.jpg)
